Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two leading medications for combating obesity and type 2 diabetes. While both belong to the GLP-1 receptor agonist class, they differ fundamentally in their mechanism of action, efficacy, side effect profiles,…